IL13RA2 and mesothelioma: Takenouchi et al. showed that combination of anti-IL-13Rα2 with DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine, which augmented IL-13Rα2 expression with epigenetic modulation in malignant mesotheliomas, significantly prolonged the survival of mice with mesothelioma xenografts [139].